Pressmeddelande

BioStock: Curasight on the agreement with Curium

Cision Publicerad: 10 May 2023 09:45

Copenhagen-based Curasight has worked tirelessly to secure a partnership deal for uTRACE. Now, the company finally announces that it has reached a deal with global radiopharmaceuticals specialist Curium, regarding the diagnosis of prostate cancer patients. The agreement include milestone payments of up to 70 MUSD, plus double-digit royalties on future sales. BioStock invited CEO Ulrich Krasilnikoff and Chief Scientific Officer Andreas Kjaer to the studio to learn more about what this means for the company.

See the full interview at biostock.se:

https://www.biostock.se/en/2023/05/curasight-on-the-agreement-with-curium/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Nyheter om Curasight

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!